Page last updated: 2024-12-05

cyclooctanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cyclooctanone is a cyclic ketone with the formula (CH2)7CO. It is a colorless liquid with a pungent odor. Cyclooctanone is a versatile starting material for the synthesis of other organic compounds, including pharmaceuticals and agrochemicals. Its synthesis involves various methods, including the oxidation of cyclooctanol. The study of cyclooctanone is driven by its unique ring strain and its potential applications in organic synthesis. Due to its ring strain, cyclooctanone exhibits a high reactivity, making it a valuable building block for various reactions. Moreover, its ability to undergo ring-opening reactions has attracted significant interest in the field of organic chemistry. Cyclooctanone is also known to exhibit biological activity. However, further research is needed to fully explore its pharmacological effects and potential therapeutic applications.'

Cross-References

ID SourceID
PubMed CID10403
CHEMBL ID18737
SCHEMBL ID181981
MeSH IDM0129909

Synonyms (37)

Synonym
unii-z4go9p8suz
z4go9p8suz ,
4-07-00-00049 (beilstein handbook reference)
brn 1280738
einecs 207-940-2
nsc 9475
nsc9475
502-49-8
cyclooctanone
wln: l8vtj
nsc-9475
inchi=1/c8h14o/c9-8-6-4-2-1-3-5-7-8/h1-7h
cyclooctanone, 98%
CHEMBL18737 ,
bdbm50028793
AKOS000119617
cyclooctanon
BBL011399
STL146503
FT-0624240
SCHEMBL181981
cyclo-octanone
DTXSID3060114
STR03048
2,3,6,7-tetramethyl-naphthalene-1,4-dicarboxylicacid
CS-W007564
F0001-1312
mfcd00001754
cyclooctanone, vetec(tm) reagent grade, 98%
cyclooclanone
azelaone
BCP09447
Q20054504
AMY3996
cyclooctanone; cyclooctan-1-one
EN300-19677
Z104474712
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcription intermediary factor 1-alphaHomo sapiens (human)IC50 (µMol)0.16630.13581.837910.0000AID1619194
Phenylethanolamine N-methyltransferaseBos taurus (cattle)IC50 (µMol)72.00000.96005.32008.0000AID155162
E3 ubiquitin-protein ligase TRIM33Homo sapiens (human)IC50 (µMol)0.24980.23351.01654.6900AID1619193
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
transcription by RNA polymerase IITranscription intermediary factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionTranscription intermediary factor 1-alphaHomo sapiens (human)
protein ubiquitinationTranscription intermediary factor 1-alphaHomo sapiens (human)
protein catabolic processTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of protein stabilityTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of apoptotic processTranscription intermediary factor 1-alphaHomo sapiens (human)
response to peptide hormoneTranscription intermediary factor 1-alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription intermediary factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription intermediary factor 1-alphaHomo sapiens (human)
epithelial cell proliferationTranscription intermediary factor 1-alphaHomo sapiens (human)
negative regulation of epithelial cell proliferationTranscription intermediary factor 1-alphaHomo sapiens (human)
calcium ion homeostasisTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of vitamin D receptor signaling pathwayTranscription intermediary factor 1-alphaHomo sapiens (human)
cellular response to estrogen stimulusTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of signal transduction by p53 class mediatorTranscription intermediary factor 1-alphaHomo sapiens (human)
methylationPhenylethanolamine N-methyltransferaseBos taurus (cattle)
epinephrine biosynthetic processPhenylethanolamine N-methyltransferaseBos taurus (cattle)
negative regulation of transcription by RNA polymerase IIE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
protein ubiquitinationE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwayE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
negative regulation of BMP signaling pathwayE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
negative regulation of DNA-templated transcriptionE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
methylated histone bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
p53 bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
chromatin bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
transcription coactivator activityTranscription intermediary factor 1-alphaHomo sapiens (human)
protein kinase activityTranscription intermediary factor 1-alphaHomo sapiens (human)
signaling receptor bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
protein bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
zinc ion bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
nuclear receptor bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
estrogen response element bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase activityTranscription intermediary factor 1-alphaHomo sapiens (human)
lysine-acetylated histone bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
phenylethanolamine N-methyltransferase activityPhenylethanolamine N-methyltransferaseBos taurus (cattle)
DNA bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
ubiquitin-protein transferase activityE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
protein bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
zinc ion bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
co-SMAD bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
R-SMAD bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
male germ cell nucleusTranscription intermediary factor 1-alphaHomo sapiens (human)
nucleusTranscription intermediary factor 1-alphaHomo sapiens (human)
nucleoplasmTranscription intermediary factor 1-alphaHomo sapiens (human)
perichromatin fibrilsTranscription intermediary factor 1-alphaHomo sapiens (human)
mitochondrionTranscription intermediary factor 1-alphaHomo sapiens (human)
cytosolTranscription intermediary factor 1-alphaHomo sapiens (human)
euchromatinTranscription intermediary factor 1-alphaHomo sapiens (human)
chromatinTranscription intermediary factor 1-alphaHomo sapiens (human)
nucleusE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
nucleoplasmE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
chromatinE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID155162Inhibitory activity against phenylethanolamine N-methyl-transferase1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Importance of the aromatic ring in adrenergic amines. 5. Nonaromatic analogues of phenylethanolamine as inhibitors of phenylethanolamine N-methyltransferase: role of hydrophobic and steric interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (15.38)18.7374
1990's2 (15.38)18.2507
2000's6 (46.15)29.6817
2010's3 (23.08)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.00 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]